We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,223

Methods of medical treatment and dosage claims
  • Gowling WLG
  • Canada
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada


Novopharm Limited v. Eli Lilly and Company (2010 FC 915)
  • Gowling WLG
  • Canada
  • October 27 2010

An impeachment action was brought by Novopharm in respect of a patent for STRATTERA alleging obviousness, anticipation, utility and improper selection


Supreme Court hearing may resolve critical questions in Canadian patent law
  • Blake Cassels & Graydon LLP
  • Canada
  • March 28 2016

The Supreme Court of Canada (SCC) recently granted AstraZeneca Canada Inc. et al. (AstraZeneca) leave to appeal from the Federal Court of Appeal’s


Biosimilar Approvals in the US and Canada - Sidestepping the 'Patent Dance'
  • Bereskin & Parr LLP
  • Canada, USA
  • January 12 2016

A passing moment of social awkwardness between a couple on a dance floor is nothing compared to the situation when the sidestepping is between two


Approvability of generic NOC satisfies imminence criteria in quia timet proceedings
  • Gowling WLG
  • Canada
  • April 7 2016

The Federal Court in Gilead Sciences Inc v Teva Canada Limited, 2016 FC 336 has clarified the law with respect to the imminence requirement of future


Leave to Appeal to SCC: AstraZeneca Canada Inc et al v Apotex Inc et al (FCCA)
  • Bereskin & Parr LLP
  • Canada
  • March 10 2016

On March 10, 2016, the Supreme Court of Canada granted AstraZeneca Canada Inc.'s ("AstraZeneca") application for leave to appeal from the decision of


Dispelling the Myriad gene patent harmonization myth
  • Foley & Lardner LLP
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the


The Myriad decision: what is the impact?
  • Bereskin & Parr LLP
  • Canada
  • June 20 2013

As we reported in our previous article, the Supreme Court of the United States issued its long awaited decision in the Myriad case on June 13, 2013


Canadian patent term extension is coming
  • Bereskin & Parr LLP
  • Canada, European Union
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian


Reply affidavits allowed when new documents introduced in responding evidence
  • Borden Ladner Gervais LLP
  • Canada
  • January 9 2014

In this case, there is a partial reversal of evidence. Apotex brought a motion for leave to file reply evidence. Allergan did not oppose parts of the